CHUNLI MEDICAL (01858.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.

Gelonghui reported on March 18 that CHUNLI MEDICAL (01858.HK) announced that a Board of Directors meeting will be held on March 28, 2025 (Friday), for the purpose of approving the annual performance announcement for the fiscal year ending December 31, 2024, and considering the payment of a final dividend (if any).

Gelonghui FinanceMar 18 16:53

CHUNLI MEDICAL: NOTICE OF BOARD MEETING

HKEXMar 18 16:35 · Announcements

Hong Kong stock Concept tracking | Deepseek sparks an AI Medical craze, increasing the valuation of the Medical Sector (including Concept stocks).

Frost & Sullivan predicts that by 2033, the Medical AI market in China will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%.

Zhitong FinanceMar 7 09:41

CHUNLI MEDICAL (688236.SH): A total of 0.226% of the company's shares have been repurchased.

On March 4, Gelonghui reported that CHUNLI MEDICAL (688236.SH) announced that as of February 28, 2025, the company has cumulatively repurchased 868,145 shares of its stock through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.226% of the company's total share capital. The highest price for the buyback was 15.96 yuan per share, the lowest was 12.09 yuan per share, and the total amount of funds paid was 12,018,864.19 yuan (excluding transaction fees).

Gelonghui FinanceMar 4 17:16

Hong Kong stocks movement | CHUNLI MEDICAL (01858) fell over 5%, significantly impacted by the centralized procurement policy. The company's net profit decreased by 55% year-on-year last year.

CHUNLI MEDICAL (01858) fell more than 5%. As of the time of this report, it has decreased by 5.13%, priced at 8.7 Hong Kong dollars, with a transaction volume of 2.8645 million Hong Kong dollars.

Zhitong FinanceFeb 28 11:06

Announcement Summary | Several Biomedical stocks announced their Earnings Reports, BEIGENE's revenue increased by 56% year-on-year last year.

① BEIGENE's revenue exceeds 27 billion yuan in 2024, how is the profitability? ② SHK PPT's mid-term profit decreased by nearly 20%, how significant is the impact?

cls.cnFeb 28 08:27